VADS REACH (GORTEC 2017-01) A Phase III Randomized Trial of Avelumab-cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Paris
Appareil Digestif SCARCE (C17-02 PRODIGE 60) A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma Paris
Recherches "plusieurs pathologies" NIPINEC (GCO-001) A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) Paris NICOLAS GIRARD
Sein métastatique RH+ XENERA-1 (BI 1280-0022) A multi-centre, double-blind, placebo-controlled,randomised phase II trial to compare efficacy of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in post-menopausal women with HR+ / HER2- metastatic breast cancer and non-visceral disease Paris
Recherches "plusieurs pathologies" CA209-848 A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) Paris EMANUELA ROMANO
Gynécologie - Ovaires FIRST 3000-03-005/ENGOT-OV44 A Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (FIRST) Paris, Saint-Cloud
Recherches "plusieurs pathologies" ARIANES A multicenter, open label, phase II basket trial exploring the efficacy and safety of the combination of rucaparib (PARP inhibitor) and atezolizumab (anti-PD-L1 antibody) in patients with DNA repair-deficient or platinum-sensitive solid tumors Paris
VADS CA209-9T9 ProNiHN A FRENCH, PROSPECTIVE, NON-INTERVENTIONAL RESEARCH (NIR) OF NIVOLUMAB IN PATIENTS WITH SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) PROGRESSING ON OR AFTER PLATINUM-BASED THERAPY Paris CHRISTOPHE LE TOURNEAU
Sein métastatique RH+ EMERALD ELACESTRANT MONOTHERAPY VS. STANDARD OF CARE FOR THE TREATMENT OF PATIENTS WITH ER+/HER2- ADVANCED BREAST CANCER FOLLOWING CDK4/6 INHIBITOR THERAPY: A PHASE 3 RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED, MULTICENTER TRIAL Paris, Saint-Cloud
Recherches "plusieurs pathologies" MS1000070-176 An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies Paris